Literature DB >> 11346194

The clinical implications of weight gain in schizophrenia.

I Kurzthaler1, W W Fleischhacker.   

Abstract

The tendency of most of the second generation antipsychotics to induce weight gain to a larger extent than that of traditional neuroleptics has renewed the interest in weight problems of patients with schizophrenia. Drug-induced weight gain has been identified as a major risk factor for various medical disorders that might be responsible for the increased morbidity and mortality rates of patients suffering from schizophrenia. Also, it has a major impact on compliance. This article focuses on the clinical relevance of increased body weight in schizophrenia. It outlines screening and management options to prevent and/or manage weight gain associated with schizophrenia in everyday clinical practice. The first strategies should be to identify obesity-prone patients at the beginning of treatment and provide information (to patients and caregivers) about the risks of weight gain and its consequences. Additionally, the possibility of weight gain calls for a regular monitoring of weight and weight-related laboratory parameters. The patients should also be offered dietary advice as well as regular exercise and behavior modification programs. Physicians must be aware of the problem of weight gain associated with schizophrenia and choose antipsychotic medication carefully, especially in patients at high risk for weight gain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11346194

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  28 in total

1.  The poor physical health of people with mental illness.

Authors:  D P Osborn
Journal:  West J Med       Date:  2001-11

Review 2.  Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders.

Authors:  Julie Pongrac; Frank A Middleton; David A Lewis; Pat Levitt; Károly Mirnics
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

3.  Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.

Authors:  Mikhail Kalinichev; Claire Rourke; Alex J Daniels; Mary K Grizzle; Christy S Britt; Diane M Ignar; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 4.  Physical Health and Drug Safety in Individuals with Schizophrenia.

Authors:  Tamara Pringsheim; Martina Kelly; Doug Urness; Michael Teehan; Zahinoor Ismail; David Gardner
Journal:  Can J Psychiatry       Date:  2017-07-18       Impact factor: 4.356

Review 5.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 6.  Interventions to reduce weight gain in schizophrenia.

Authors:  G Faulkner; T Cohn; G Remington
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

7.  Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.

Authors:  Gabriela Balf; Thomas D Stewart; Richard Whitehead; Ross A Baker
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 8.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 9.  Ten putative contributors to the obesity epidemic.

Authors:  Emily J McAllister; Nikhil V Dhurandhar; Scott W Keith; Louis J Aronne; Jamie Barger; Monica Baskin; Ruth M Benca; Joseph Biggio; Mary M Boggiano; Joe C Eisenmann; Mai Elobeid; Kevin R Fontaine; Peter Gluckman; Erin C Hanlon; Peter Katzmarzyk; Angelo Pietrobelli; David T Redden; Douglas M Ruden; Chenxi Wang; Robert A Waterland; Suzanne M Wright; David B Allison
Journal:  Crit Rev Food Sci Nutr       Date:  2009-11       Impact factor: 11.176

10.  An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia.

Authors:  Giorgio L Colombo; Mauro Caruggi; Sergio Di Matteo; Alessandro Rossi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.